VER.L

Vernalis Plc
Vernalis PLC - Block listing Interim Review
1st October 2018, 13:57
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5737C
Vernalis PLC
01 October 2018
 

BLOCK LISTING SIX MONTHLY RETURN AND BLOCK LISTING APPLICATION

 

VERNALIS PLC (the "Company")

 

1 October 2018

 

Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 

Name of applicant:

Vernalis plc

Name of scheme(s):

2007 Long Term Incentive Scheme ("LTIP"); 2012 Value Builder Plan ("VBP"); and

2016 Executive Incentive Plan ("EIP")

Period of return (from / to):

From: 29/Mar/2018

To: 01/Oct/2018

Balance of unallotted securities under scheme(s) from previous return:

Total of 2,149,159 Ordinary 1p Shares, split:

· Under LTIP   =   360,485 Ordinary 1p Shares

· Under VBP    =   1,788,674 Ordinary 1p Shares

· Under EIP     =   nil Ordinary 1p Shares

Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period:

Total of 166,376 Ordinary 1p Shares, split:

· Under LTIP   =   39,405 Ordinary 1p Shares

· Under VBP    =   126,971 Ordinary 1p Shares

Less: Number of securities forfeited under scheme(s) during period:

Total of 30,526 Ordinary 1p Shares:

· Under LTIP   =   30,526 Ordinary 1p Shares

· Under VBP    =   nil Ordinary 1p Shares

· Under EIP     =   nil Ordinary 1p Shares

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

Total of 1,952,257 Ordinary 1p Shares, split:

· Under LTIP   =   290,554 Ordinary 1p Shares

· Under VBP    =   1,661,703 Ordinary 1p Shares

· Under EIP     =   nil Ordinary 1p Shares

Number and class of securities originally admitted and the date of admission (including any additions):

No. of Ordinary 1p Shares

Date on which Shares were Admitted to Trading

350,000

6 November 2013, plus

1,049,317

12 May 2014, plus

1,058,184

12 May 2015, plus

1,638,364

30 September 2015, plus

1,189,296

1 April 2016, plus

499,612

31 March 2017, plus

1,788,674

2 October 2017, plus

95,654

5 April 2018

 

-- ends --

 

Enquiries:

 

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer

 


Canaccord plc (Nominated Adviser and Broker):

+44 (0) 20 7523 8000

Henry Fitzgerald-O'Connor

Emma Gabriel

 


Evercore (Financial Adviser):

+44 (0) 20 7653 6000

Julian Oakley

Alan Beirne

 


 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, pharmaceutical company with significant expertise in drug development. The Group has two approved products: Moxatag®, a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. Vernalis has also nine programmes in its NCE development pipeline in addition to significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis and Servier.

 

For further information about Vernalis, please visit www.vernalis.com. 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRMBBJTMBAMBJP ]]>
TwitterFacebookLinkedIn